MD4664B1 - Lactame aril şi heteroaril condensate - Google Patents
Lactame aril şi heteroaril condensate Download PDFInfo
- Publication number
- MD4664B1 MD4664B1 MDA20150052A MD20150052A MD4664B1 MD 4664 B1 MD4664 B1 MD 4664B1 MD A20150052 A MDA20150052 A MD A20150052A MD 20150052 A MD20150052 A MD 20150052A MD 4664 B1 MD4664 B1 MD 4664B1
- Authority
- MD
- Moldova
- Prior art keywords
- lactams
- heteroaryl
- condensed aryl
- compounds
- salts
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 title 1
- -1 heteroaryl lactams Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Prezenta invenţie se referă la compuşii cu formula generală:(II-A)în care R1, R2, R3, R4, R5, m, X, Y şi Z au semnificaţiile definite în descriere, şi la sărurile farmaceutic acceptabile ale acestora, la compoziţii farmaceutice care conţin aceşti compuşi şi săruri, şi la metode de utilizare a acestor compuşi, săruri şi compoziţii pentru tratamentul creşterii anormale a celulelor, inclusiv al cancerului.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740596P | 2012-12-21 | 2012-12-21 | |
| PCT/IB2013/060682 WO2014097041A1 (en) | 2012-12-21 | 2013-12-05 | Aryl and heteroaryl fused lactams |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD20150052A2 MD20150052A2 (ro) | 2015-12-31 |
| MD4664B1 true MD4664B1 (ro) | 2019-12-31 |
| MD4664C9 MD4664C9 (ro) | 2020-07-31 |
Family
ID=49917684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20150052A MD4664C9 (ro) | 2012-12-21 | 2013-12-05 | Lactame aril şi heteroaril condensate |
Country Status (46)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| AU2013216721B2 (en) | 2012-02-10 | 2017-09-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| KR102788773B1 (ko) | 2012-12-21 | 2025-03-28 | 얀센 바이오파마, 인코퍼레이트. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체 |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2015023915A1 (en) | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| DK3157915T3 (en) * | 2014-06-17 | 2019-04-23 | Pfizer | Substituted dihydroisoquinolinone compounds |
| WO2015193768A1 (en) * | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Aryl fused lactams as ezh2 modulators |
| US20170334891A1 (en) * | 2014-10-28 | 2017-11-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US20180271857A1 (en) | 2014-12-23 | 2018-09-27 | University Of Copenhagen | Treatment of cancer by inhibiting ezh2 activity |
| CR20170418A (es) * | 2015-03-27 | 2017-11-09 | Syngenta Participations Ag | Derivados heterobicíclicos microbicidas |
| TW201708210A (zh) * | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產（第二）有限公司 | Ｚｅｓｔｅ同源物２增強子之抑制劑 |
| TW201718598A (zh) * | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
| ES2760510T3 (es) | 2015-11-19 | 2020-05-14 | Jiangsu Hengrui Medicine Co | Derivado de benzofurano, método de preparación del mismo y uso del mismo en medicina |
| BR112018072740A2 (pt) * | 2016-05-05 | 2019-02-19 | Glaxosmithkline Intellectual Property (No. | realçador de inibidores de homólogo 2 de zeste |
| CN109843870A (zh) | 2016-10-19 | 2019-06-04 | 星座制药公司 | Ezh2抑制剂的合成 |
| US20200262813A1 (en) * | 2016-11-11 | 2020-08-20 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 1,5,7-trisubstituted isoquinoline derivatives, preparation thereof, and use thereof in medicines |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| MX386586B (es) | 2017-05-18 | 2025-03-19 | Jiangsu Hengrui Medicine Co | Cristal de base libre de derivados benzofurano y método de preparación. |
| CN109937041B (zh) | 2017-05-18 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途 |
| CN106977483A (zh) * | 2017-06-02 | 2017-07-25 | 遵义医学院 | 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法 |
| RU2754131C1 (ru) | 2017-11-14 | 2021-08-27 | Пфайзер Инк. | Комбинированная терапия ингибитором ezh2 |
| FI4043466T3 (fi) | 2018-01-31 | 2024-10-30 | Mirati Therapeutics Inc | Prc2:n estäjiä |
| EP3813784B1 (en) * | 2018-06-07 | 2024-01-10 | The Regents Of The University Of Michigan | Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith |
| WO2020011607A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| EP3870173A4 (en) * | 2018-10-24 | 2022-06-22 | Vanderbilt University | WDR5 INHIBITORS AND MODULATORS |
| CN111320582A (zh) * | 2018-12-17 | 2020-06-23 | 江苏恩华药业股份有限公司 | 一种类酰胺类衍生物及其中间体的制备方法 |
| KR102689665B1 (ko) * | 2019-02-19 | 2024-07-31 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
| EP3959214A1 (en) | 2019-04-22 | 2022-03-02 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as prc2 inhibitors |
| JP7541538B2 (ja) | 2019-06-05 | 2024-08-28 | ミラティ セラピューティクス，インク． | 癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体 |
| KR102386403B1 (ko) * | 2020-08-13 | 2022-04-15 | 한미약품 주식회사 | 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도 |
| UA129557C2 (uk) | 2020-08-13 | 2025-05-28 | Ханмі Фармасьютікал Ко., Лтд. | Похідні діоксолоізохінолінону та їх застосування |
| WO2022179584A1 (zh) * | 2021-02-26 | 2022-09-01 | 南京药石科技股份有限公司 | 新型ezh2抑制剂及其用途 |
| CN120476107A (zh) | 2022-12-15 | 2025-08-12 | 先正达农作物保护股份公司 | 可用作杀有害生物剂的新型的二环-甲酰胺化合物 |
| CN118978498B (zh) * | 2024-10-22 | 2025-04-01 | 浙江雅辰药物科技股份有限公司 | 一种5-羟甲基四氢呋喃-3-醇的制备方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3846412A (en) | 1971-03-18 | 1974-11-05 | Lepetit Spa | Dihydro-2-amino-isoquinolines and their derivatives |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| WO2007022280A1 (en) | 2005-08-16 | 2007-02-22 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| WO2011103016A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| US8637509B2 (en) | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
| SG185431A1 (en) | 2010-05-07 | 2012-12-28 | Glaxosmithkline Llc | Indoles |
| KR102511807B1 (ko) | 2010-09-10 | 2023-03-20 | 에피자임, 인코포레이티드 | 인간 ｅｚｈ2의 억제제 및 이의 사용 방법 |
| WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3323820B1 (en) * | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| EP2760452A4 (en) | 2011-09-30 | 2015-04-01 | Glaxosmithkline Llc | METHOD FOR TREATING CARCINOMA |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| US20150239842A1 (en) | 2012-09-28 | 2015-08-27 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
| FR3000065A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
| KR102788773B1 (ko) | 2012-12-21 | 2025-03-28 | 얀센 바이오파마, 인코퍼레이트. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체 |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| CA2894765A1 (en) | 2012-12-21 | 2014-06-26 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| SMT201800230T1 (it) | 2012-12-21 | 2018-07-17 | Plexxikon Inc | Composti e metodi per la modulazione della chinasi e loro indicazioni |
| EA026687B1 (ru) | 2012-12-21 | 2017-05-31 | Ф. Хоффманн-Ля Рош Аг | Пептиды в качестве агонистов окситоцина |
| ME02400B (me) | 2012-12-21 | 2016-09-20 | Gilead Sciences Inc | Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba |
| FR3000059A1 (fr) | 2012-12-21 | 2014-06-27 | Saint Gobain Placo | Composition pour plaques de platre et produits obtenus |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| LT2935222T (lt) | 2012-12-21 | 2018-12-27 | Epizyme, Inc. | Prmt5 slopikliai ir jų panaudojimas |
| DK3157915T3 (en) | 2014-06-17 | 2019-04-23 | Pfizer | Substituted dihydroisoquinolinone compounds |
-
2013
- 2013-05-12 UA UAA201505087A patent/UA111305C2/uk unknown
- 2013-12-05 EP EP17206218.4A patent/EP3339303B9/en active Active
- 2013-12-05 CA CA2893339A patent/CA2893339C/en active Active
- 2013-12-05 RS RS20200917A patent/RS60582B9/sr unknown
- 2013-12-05 PL PL17206218T patent/PL3339303T3/pl unknown
- 2013-12-05 LT LTEP17206218.4T patent/LT3339303T/lt unknown
- 2013-12-05 SI SI201331756T patent/SI3339303T1/sl unknown
- 2013-12-05 MX MX2015008058A patent/MX2015008058A/es active IP Right Grant
- 2013-12-05 HR HRP20180060TT patent/HRP20180060T1/hr unknown
- 2013-12-05 CN CN201380066782.2A patent/CN104870435B/zh not_active Expired - Fee Related
- 2013-12-05 SI SI201330958T patent/SI2935238T1/en unknown
- 2013-12-05 MA MA38175A patent/MA38175B1/fr unknown
- 2013-12-05 PT PT172062184T patent/PT3339303T/pt unknown
- 2013-12-05 HU HUE17206218A patent/HUE050009T2/hu unknown
- 2013-12-05 CR CR20200273A patent/CR20200273A/es unknown
- 2013-12-05 LT LTEP13817739.9T patent/LT2935238T/lt unknown
- 2013-12-05 EP EP13817739.9A patent/EP2935238B1/en active Active
- 2013-12-05 MY MYPI2020003405A patent/MY192259A/en unknown
- 2013-12-05 MY MYPI2015701733A patent/MY176307A/en unknown
- 2013-12-05 MD MDA20150052A patent/MD4664C9/ro not_active IP Right Cessation
- 2013-12-05 ES ES13817739.9T patent/ES2658974T3/es active Active
- 2013-12-05 CU CU2015000062A patent/CU24414B1/es unknown
- 2013-12-05 SG SG11201504076XA patent/SG11201504076XA/en unknown
- 2013-12-05 TR TR2018/02791T patent/TR201802791T4/tr unknown
- 2013-12-05 KR KR1020157019806A patent/KR101712441B1/ko not_active Expired - Fee Related
- 2013-12-05 JP JP2015548808A patent/JP5909308B2/ja active Active
- 2013-12-05 PT PT138177399T patent/PT2935238T/pt unknown
- 2013-12-05 DK DK13817739.9T patent/DK2935238T3/en active
- 2013-12-05 AP AP2015008574A patent/AP2015008574A0/xx unknown
- 2013-12-05 AU AU2013365908A patent/AU2013365908C1/en not_active Ceased
- 2013-12-05 ME MEP-2020-147A patent/ME03793B/me unknown
- 2013-12-05 WO PCT/IB2013/060682 patent/WO2014097041A1/en not_active Ceased
- 2013-12-05 HU HUE13817739A patent/HUE038238T2/hu unknown
- 2013-12-05 BR BR112015014678-3A patent/BR112015014678B1/pt not_active IP Right Cessation
- 2013-12-05 PE PE2015001044A patent/PE20151090A1/es active IP Right Grant
- 2013-12-05 RS RS20180103A patent/RS56815B1/sr unknown
- 2013-12-05 ES ES17206218T patent/ES2808987T3/es active Active
- 2013-12-05 EA EA201590879A patent/EA028317B1/ru unknown
- 2013-12-05 PL PL13817739T patent/PL2935238T3/pl unknown
- 2013-12-05 NZ NZ708801A patent/NZ708801A/en not_active IP Right Cessation
- 2013-12-05 GE GEAP201313863A patent/GEP201706718B/en unknown
- 2013-12-05 DK DK17206218.4T patent/DK3339303T3/da active
- 2013-12-18 US US14/132,567 patent/US9040515B2/en active Active
- 2013-12-18 TW TW102146910A patent/TWI546293B/zh not_active IP Right Cessation
- 2013-12-19 AR ARP130104902A patent/AR094174A1/es not_active Application Discontinuation
- 2013-12-20 UY UY0001038712A patent/UY38712A/es not_active Application Discontinuation
- 2013-12-20 UY UY0001035225A patent/UY35225A/es not_active Application Discontinuation
-
2014
- 2014-02-28 NO NO14709442A patent/NO2961649T3/no unknown
-
2015
- 2015-03-09 US US14/642,274 patent/US20150175572A1/en not_active Abandoned
- 2015-05-26 CR CR20150279A patent/CR20150279A/es unknown
- 2015-06-16 PH PH12015501367A patent/PH12015501367B1/en unknown
- 2015-06-18 IL IL239520A patent/IL239520B/en active IP Right Grant
- 2015-06-18 CL CL2015001733A patent/CL2015001733A1/es unknown
- 2015-06-18 TN TNP2015000281A patent/TN2015000281A1/fr unknown
- 2015-06-19 DO DO2015000157A patent/DOP2015000157A/es unknown
- 2015-06-19 GT GT201500190A patent/GT201500190A/es unknown
- 2015-06-19 MX MX2020002924A patent/MX2020002924A/es unknown
- 2015-06-19 ZA ZA2015/04437A patent/ZA201504437B/en unknown
- 2015-07-21 EC ECIEPI201531579A patent/ECSP15031579A/es unknown
-
2017
- 2017-05-03 US US15/585,880 patent/US10246433B2/en active Active
-
2018
- 2018-02-05 CY CY20181100137T patent/CY1119883T1/el unknown
- 2018-09-05 ME MEP-2018-8A patent/ME02980B/me unknown
-
2020
- 2020-07-30 HR HRP20201194TT patent/HRP20201194T2/hr unknown
- 2020-08-11 CY CY20201100746T patent/CY1123237T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD4664B1 (ro) | Lactame aril şi heteroaril condensate | |
| PH12020550552A1 (en) | Inhibitors of hepatitis c virus | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| EA201190235A1 (ru) | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 | |
| EA202090486A2 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| JO3807B1 (ar) | مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها | |
| EA201491672A1 (ru) | Гетероциклильные соединения как ингибиторы mek | |
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| EA201490673A1 (ru) | Производные пирролопиримидина и пурина | |
| EA201201661A1 (ru) | Новые аминопиразолохиназолины | |
| EA201591195A1 (ru) | Новые хинолоновые производные | |
| EA201201677A1 (ru) | Производные гетероарилимидазолона в качестве ингибиторов jak | |
| PH12013501543A1 (en) | Hepatitis c virus inhibitors | |
| EA201600337A1 (ru) | 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний | |
| EA201490438A1 (ru) | Антибактериальные 3,4-дигидро-1н-[1,8]нафтиридиноны, замещенные циклопента[c]пирролом | |
| EA201490435A1 (ru) | Антибактериальные 3,4-дигидро-1н-[1,8]нафтиридиноны, замещенные пиперидинилом | |
| EA201590787A1 (ru) | Замещенные пиридопиразины в качестве ингибиторов syk | |
| EA201590339A1 (ru) | Новые антибактериальные соединения | |
| EA201490436A1 (ru) | Антибактериальные 3,4-дигидро-1н-[1,8]нафтиридиноны, замещенные гомопиперидинилом | |
| IN2014DN09314A (ro) | ||
| EA201600323A1 (ru) | Производные пиперазина и их применение в качестве лекарственного средства | |
| EA201650003A1 (ru) | Соединённые циклоалкилом дигетероциклические производные | |
| EA201590331A1 (ru) | Новые антибактериальные соединения | |
| EA201201668A1 (ru) | Δ-кристаллическая форма аргининовой соли периндоприла, способ ее получения и содержащие ее фармацевтические композиции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued | ||
| KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |